AB-2100

· Arsenal Biosciences, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for AB-2100, covering 2025-09-22 to 2025-09-22. Get the full timeline:

Most recent: Clinical Trial Update: AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC) [Phase 1, Phase 2]

See pricing